Gift of $1.5 million will fund DMT research at UC San Diego

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

The gov­ern­ment’s first of­fer to As­traZeneca un­der the IRA’s drug price ne­go­ti­a­tions that be­gan this month is “rel­a­tive­ly en­cour­ag­ing,” CEO Pas­cal So­ri­ot said Thurs­day, at